GlassScriptPhysician profile
Eugene Rosenman
NPI 1659433787
$4,963.34
in general payments reported to CMS, 2019-2025
24 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $443 · 2021: $1,216 · 2022: $1,340 · 2023: $133 · 2024: $308 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $635.82 | 2019-2024 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $576.78 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $563.57 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $487.84 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $452.62 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $421.21 | 2019-2024 | Spravato |
| Abbvie INC. | $418.60 | 2021-2024 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $211.18 | 2019-2025 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $180.31 | 2021-2025 | Qelbree |
| Tris Pharma INC | $169.45 | 2021-2024 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $128.60 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.58 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $96.80 | 2019-2022 | |
| Indivior INC. | $94.22 | 2021-2025 | Sublocade |
| Lilly USA, LLC | $69.44 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $66.43 | 2019-2023 | Trintellix |
| Eisai INC. | $56.09 | 2020-2021 | |
| Shire North American Group INC | $47.11 | 2019 | |
| Avanir Pharmaceuticals, INC. | $44.41 | 2020-2022 | |
| Allergan, INC. | $41.29 | 2020 | |
| Merck Sharp & Dohme LLC | $20.75 | 2022 | |
| Axsome Therapeutics, INC. | $20.48 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.22 | 2022 | |
| Neuronetics, INC. | $15.54 | 2023 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Rosenman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.